Sign In
Get Clay Free →

Suggestions

    Stephen Martin

    Global Head of Research at Boehringer Ingelheim Animal Health

    Stephen Martin was previously the Global Head of Research at Boehringer Ingelheim Animal Health, but he has since left the company. He announced his departure from Boehringer-Ingelheim Animal Health in June 2023 after more than 30 years in the pharmaceutical and animal health industry.3

    During his tenure at Boehringer Ingelheim Animal Health, Martin played a significant role in the company's research initiatives. He was involved in collaborative efforts to develop innovative solutions in animal health, including a partnership with MabGenesis to discover and develop novel monoclonal antibodies for potential canine therapeutic treatments.1

    Martin has extensive knowledge and experience in all sectors of the biological and pharmaceutical business.2 His career spans over three decades, during which he worked for various prominent companies in the industry, including Merial, Novartis Animal Health, Upjohn, and Boehringer Ingelheim Animal Health.4

    As of January 2025, Stephen Martin is self-employed, leveraging his vast experience in the pharmaceutical and animal health sectors.24

    Highlights

    Collaboration to develop monoclonal antibodies - Veterinary Practice

    Related Questions

    What are Stephen Martin's key achievements at Boehringer Ingelheim Animal Health?
    How has Stephen Martin contributed to the development of monoclonal antibodies in animal health?
    What inspired Stephen Martin to leave Boehringer Ingelheim after 30+ years?
    What are some notable projects Stephen Martin has worked on in the pharmaceutical industry?
    How does Stephen Martin's experience at Merial and Novartis Animal Health influence his current role?
    Stephen Martin
    Get intro to Stephen
    Add to my network

    Location

    Duluth, Georgia, United States